GlaxoSmithKline and Warp Drive Bio have entered a partnership to unlock 80% of human proteins considered “undruggable.” This innovation in biotechnology would enable drugs to better fight niche diseases. GSK will be bringing its DNA encoded library to the deal, ensuring a vast array of molecules. Warp Drive Bio will be offering the use of its SMART platform which enable molecules to fuse to cells and operate within them. Read the full article here.